[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343049-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343049-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","integrating-molecular-insights-into-biliary-tract-cancer-management-a-review-of-personalized-therapeutic-strategies","Integrating Molecular Insights into Biliary Tract Cancer Management - A Review of Personalized Therapeutic Strategies","","Biliary tract cancers (BTCs) are rare, aggressive malignancies with rising incidence and poor prognosis. Standard systemic therapy has expanded to include immune checkpoint inhibitors combined with gemcitabine–cisplatin as first-line treatment, yet outcomes remain limited. Molecular profiling is emphasized as a critical early step to match patients with actionable genetic alterations such as IDH1 mutations and FGFR2 fusions, support clinical trial selection, and inform individualized treatment decisions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/integrating-molecular-insights-into-biliary-tract-cancer-management-a-review-of-personalized-therapeutic-strategies/343049/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/integrating-molecular-insights-into-biliary-tract-cancer-management-a-review-of-personalized-therapeutic-strategies/343049.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is molecular profiling important in biliary tract cancer management?","Question",{"text":63,"@type":64},"Molecular profiling enables early identification of actionable genetic alterations, helps select candidates for clinical trials, and guides personalized treatment strategies based on tumor biology.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What therapies are described as part of standard first-line treatment for BTCs?",{"text":68,"@type":64},"The standard systemic treatment has evolved to include immune checkpoint inhibitors combined with gemcitabine–cisplatin as first-line therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"Which genetic alterations are highlighted as therapeutic targets?",{"text":72,"@type":64},"The review notes targets such as IDH1 mutations and FGFR2 fusions, which support development of targeted therapies and individualized management.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343049,1790190747,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nIntegrating Molecular Insights into Biliary Tract Cancer  \nManagement: A Review of Personalized Therapeutic Strategies  \nMar Ros-Buxó 1,†, Ezequiel Mauro 1,2,3,4, *,†, Tamara Sauri 1,2,5, Gemma Iserte 2,3,4, Carla Fuster-Anglada 2,3,6, Alba Díaz 1,2,3,6, Laura Sererols-Viñas 2, Silvia Affo 2 and Alejandro Forner 1,2,3,4, *  \nCitation: Ros-Buxó, M.; Mauro, E.; Sauri, T.; Iserte, G.; Fuster-Anglada, C.; Díaz, A.; Sererols-Viñas, L.; Affo, S.; Forner, A. Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies. Curr. Oncol. 2024, 31, 3615–3629 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol31070266  \nReceived: 29 May 2024  \nRevised: 17 June 2024  \nAccepted: 18 June 2024  \nPublished: 21 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 School of Medicine, Universitat de Barcelona, 08007 Barcelona, Spain; [mrosbuxo@gmail.com](mrosbuxo@gmail.com) (M.R.-B.); [sauri@clinic.cat](sauri@clinic.cat) (T.S.); [madiaz@clinic.cat](madiaz@clinic.cat) (A.D.)  \n2 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; [giserte@clinic.cat](giserte@clinic.cat) (G.I.); [fuster@clinic.cat](fuster@clinic.cat) (C.F.-A.); [lsererols@recerca.clinic.cat](lsererols@recerca.clinic.cat) (L.S.-V.); [saffo@recerca.clinic.cat](saffo@recerca.clinic.cat) (S.A.)  \n3 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd),  \n28029 Madrid, Spain  \n4 Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Institut Clínic de Malalties Digestives i Metabòliques (ICMDM), Hospital Clinic Barcelona, 08036 Barcelona, Spain  \n5 Barcelona Clinic Liver Cancer (BCLC) Group, Medical Oncology Department, Institut del Càncer i Malalties de la Sang (ICAMS), Hospital Clinic Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain  \n6 Barcelona Clinic Liver Cancer (BCLC) Group, Pathology Department, CDB, Hospital Clinic Barcelona, 08036 Barcelona, Spain  \n* [Correspondence: mauro@clinic.cat](Correspondence: mauro@clinic.cat) (E.M.); [aforner@clinic.cat](aforner@clinic.cat) (A.F.); Tel.: +34-93-2279803 (A.F.)† These authors contributed equally to this work.  \nAbstract: Biliary tract cancers (BTCs) are rare and aggressive malignancies with an increasing incidence and poor prognosis. The standard systemic treatment for BTCs has evolved to include immune checkpoint inhibitors associated with gemcitabine–cisplatin as first-line therapies. However, survival rates remain low, highlighting the critical need for personalized treatment strategies based on molecular profiling. Currently, significant advancements have been made in the molecular characterization of BTCs, where genetic alterations, such as IDH1 mutations and FGFR2 fusions, provide targets for therapy. Molecular profiling is crucial early in the management process to identify potential candidates for clinical trials and guide treatment strategy. The integration of these molecular insights into clinical practice has allowed for the development of targeted therapies, although many of them are still in the phase 2 trial stage without definitive survival benefits demonstrated in phase 3 trials. This integration of comprehensive molecular profile insights with traditional treatment approaches offers a new horizon in the personalized medicine landscape for BTCs, with the aim of significantly improving patient outcomes through precision oncology.  \nKeywords: BTC; cholangiocarcinoma; molecular profile; ESCAT; FGFR2; IDH1; BRAF; KRAS; NTRK; liver transplantation  \n1. Introduction  \nBiliary t","cbCaik6vkc038bKO","https://ap.wps.com/l/cbCaik6vkc038bKO","pdf",1520351,15,"English","# Introduction\n## Disease overview and classification\n## Risk factors and epidemiology","[{\"question\":\"Why is molecular profiling important in biliary tract cancer management?\",\"answer\":\"Molecular profiling enables early identification of actionable genetic alterations, helps select candidates for clinical trials, and guides personalized treatment strategies based on tumor biology.\"},{\"question\":\"What therapies are described as part of standard first-line treatment for BTCs?\",\"answer\":\"The standard systemic treatment has evolved to include immune checkpoint inhibitors combined with gemcitabine–cisplatin as first-line therapies.\"},{\"question\":\"Which genetic alterations are highlighted as therapeutic targets?\",\"answer\":\"The review notes targets such as IDH1 mutations and FGFR2 fusions, which support development of targeted therapies and individualized management.\"}]","Integrating Molecular Insights into Biliary Tract Cancer Management - A Review of Personalized Therapeutic Strategies | PDF",1790049595,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3233507a24dbc3ebcbff9f07d5630282.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d79422c633a801e04721a5d6aa43491e.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cfcd3aa6708cf25ae75560b51442a5c.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84ec8a2b052fb147621f2e4358971fd4.webp",980,1385]